With the fast-growing CBD sector tied up in a regulatory quagmire, hundreds of transatlantic industry players face an uncertain future.
Benjamin Alexandre-Jeanroy, of Paris-based Augur Associates is concerned that, as the French and European medical cannabis markets develop, pharmaceutical companies such as Jazz will alter their profile and stifle competition.
He said: “Jazz is trying to restrict the access of extracts to a solely pharmaceutical model, but is this the right path for cannabis as its focus is on patenting a plant?
“The question for the medical cannabis companies is whether they can come up with a more viable model. One which is in the interests of patients; one which allows for personalised treatment and choice.”
He highlighted how Jazz has deep pockets saying this level of capital is not yet available to most medical cannabis companies.
Read more here on Business Cann.